Gapping up
In reaction to earnings/guidance:
- DHR +1.6% (Q1 guidance)
Other news:
- NVCR +41% (announced an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating Fields (TTFields) in stage 4 non-small cell lung cancer (NSCLC) following platinum failure)
- RIGL +17.2% (announced positive topline results from a hase 2 clinical trial to evaluate the safety of fostamatinib for the treatment of hospitalized patients with COVID-19) VTVT +16.3% (announces that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes)
- EVGN +10.5% (announced additional positive pre-clinical results in its immuno-oncology program demonstrating efficacy of its live biotherapeutic product (LBP) consortium BMC128, this time in melanoma)
- CERE +9.7% (announces an up to $125 mln non-dilutive financing transaction with NovaQuest and Bain Capital to fund the full Phase 3 development program for Tavapadon in Parkinson's disease)
- AGC +9.5% (Grab to go pubic through partnership with AGC)
- RILY +8.4% (to join S&P SmallCap 600)
- ZLAB +7.8% (Zai Lab and Novocure (NVCR) announce an update regarding its phase 3 pivotal LUNAR trial of Tumor Treating Fields in stage 4 non-small cell lung cancer following platinum failure)
- MRNA +7.3% (benefitting following JNJ vaccine news)
- CDLX +6.1% (announces its intent to acquire Bridg for approximately $350 mln)
- ANGI +4.4% (reports monthly metrics for March)
- DMRC +3.7% (CEO to retire, names replacement)
- IMCR +3.6% (presents data from Phase 3 trial for tebentafusp)
- PFE +1.4% (benefitting following JNJ vaccine news)
Analyst comments:
- SUPN +3.7% (upgraded to Buy from Hold at Jefferies)
- IHRT +3.5% (upgraded to Buy from Underperform at BofA Securities)
- COMM +3.4% (upgraded to Buy from Hold at Deutsche Bank)
- MOS +1.7% (upgraded to Buy from Hold at Berenberg)
- FDX +1% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)